Movement Disorder News and Research

Latest Movement Disorder News and Research

TPP raises £9.6M to develop early-stage pre-clinical drug candidates

TPP Global Development, an innovative drug development company, announced today it has raised £9.6m which will be used to execute the Company's strategy to develop early-stage pre-clinical drug candidates.

19 May 2010

Being physical and mental activity delays onset of Huntington’s disease: Research

Melbourne researchers report in a study that regular physical and mental activities can delay the onset of the dreaded genetic Huntington's disease. This disease is hereditary and it goes on to destroy the brain and nerve cells leading to loss of all or most faculties. It affects one in 10,000 people between ages 30 and 50 and there is no cure. Since it is passed on to the children at least 50% of the time the decision to have children also becomes an agonizing one for many sufferers.

13 May 2010

Imperial College London and McGill University expand scientific collaboration

Neurological research and clinical care received a significant boost today as Imperial College London and McGill University of Montreal entered an agreement enabling them to work more closely together in this field.

11 May 2010

Tel Aviv University researcher pioneers 3-D occupational therapy for children with disabilities

It was her love of ballet that led her to work with children who have motor disabilities. The retired dancer, now an occupational therapist, is pioneering a new "virtual" method to analyze movement patterns in children ― and more effectively treat those with debilitating motor disorders.

28 Apr 2010

Aton Pharma acquires the U.S. marketing rights to LODOSYN tablets from BMS

Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced that it has acquired the U.S. marketing rights to LODOSYN (carbidopa) tablets from Bristol-Myers Squibb Company.

26 Apr 2010

Team of neurologists from the U.S. face Canadian neurologists in annual "Neurobowl"

In a competition modeled after TV quiz shows, a team of neurologists from the United States will face Canadian neurologists in the annual "Neurobowl®" on April 11.

12 Apr 2010

New studies supporting Teva Pharmaceutical Industries' CNS portfolio to be presented at AAN 2010

Teva Pharmaceutical Industries Ltd. today announced that several new studies supporting the company's innovative central nervous system portfolio will be presented at the 62nd American Academy of Neurology Annual Meeting in Toronto, April 10-17, 2010.

8 Apr 2010

Rexahn Pharmaceuticals submits Phase II protocol for study of Serdaxin in treatment of PD

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted a Phase II protocol to the U.S. Food and Drug Administration (FDA) for the clinical study of Serdaxin® for the treatment of Parkinson's disease (PD).

5 Apr 2010

Top neurologists to receive 2010 AAN Alliance Awards

The American Academy of Neurology will recognize the outstanding achievements of researchers in neurology during the AAN's 62nd Annual Meeting in Toronto, April 10 through 17, 2010, the world's largest gathering of neurologists with more than 2,000 presentations on the latest advances in neurologic research.

31 Mar 2010

New devices pave way for applications in cardiology and neurology

A team of cardiologists, materials scientists, and bioengineers have created and tested a new type of implantable device for measuring the heart's electrical output that they say is a vast improvement over current devices. The new device represents the first use of flexible silicon technology for a medical application.

26 Mar 2010

St. Jude Medical's Brio DBS system for treating Parkinson’s disease receives Australian TGA approval

St. Jude Medical, Inc., a global medical device company, today announced regulatory and reimbursement approval from the Australian Therapeutic Goods Administration of its Brio™ deep brain stimulation system for treating the symptoms of Parkinson’s disease.

23 Mar 2010

Rexahn Pharmaceuticals forms Parkinson’s Disease SAB to develop strategy for Serdaxin

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced the formation of its Parkinson’s Disease Scientific Advisory Board (SAB), featuring some of the leading medical researchers in neurology.

22 Mar 2010

Manhattan Pharmaceuticals to merge with Ariston Pharmaceuticals

Manhattan Pharmaceuticals, Inc. today announced it has entered into a definitive agreement and plan of merger and completed the merger transaction with Ariston Pharmaceuticals, Inc., a privately-held, specialty pharmaceutical company. As a result of the merger, Ariston became a wholly owned subsidiary of Manhattan Pharmaceuticals.

12 Mar 2010

Ampicillin activates torsinA, improves cell function to reduce movement disorders

Discovery of an antibiotic's capacity to improve cell function in laboratory tests is providing movement disorder researchers with leads to more desirable molecules with potentially similar traits, according to University of Alabama scientists co-authoring a paper publishing March 10 in the journal Disease Models & Mechanisms.

11 Mar 2010

DSPA's lurasidone NDA accepted for FDA review

Dainippon Sumitomo Pharma America, Inc., a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd., today announced that the U.S. Food and Drug Administration recently accepted for review the lurasidone New Drug Application (NDA) for the treatment of patients with acute schizophrenia. The NDA was submitted to FDA on December 30, 2009 and will receive a standard review.

10 Mar 2010

Omeros obtains exclusive license to compounds from Asubio Pharma for use in its PDE7 program

Omeros Corporation today announced that it has obtained an exclusive license to compounds from Asubio Pharma Co., Ltd. for use in its PDE7 program, which is focused on the treatment of movement disorders.

9 Mar 2010

NAF to hold third annual Ataxia Investigators Meeting in Rosemont

The National Ataxia Foundation, in conjunction with the University of Chicago program in pathobiology and translational neuroscience, will hold its third annual Ataxia Investigators Meeting March 9-11, 2010, at the Hyatt Regency O'Hare, in Rosemont, Ill. A three-day meeting for patients, caregivers and families will follow at the same location.

6 Mar 2010

Parkinson's patients find facial and vocal expression difficult to read; deep brain stimulation seems to make it worse

Scientists are beginning to find out why people with Parkinson's disease often feel socially awkward. Parkinson's patients find it harder to recognize expressions of emotion in other people's faces and voices, report two studies published by the American Psychological Association.

4 Mar 2010

Allergan celebrates 20th anniversary of BOTOX in Canada

Twenty years ago, the first approved use of BOTOX(R) (botulinum toxin type A), a neurotoxin widely used to treat several life altering medical conditions, was granted in Canada. As part of the 20th anniversary celebrations, healthcare professionals from coast to coast reflect upon the discovery, science and evolution of a therapy that has impacted the lives of millions of patients worldwide.

3 Mar 2010

Focal dystonia precipitated by odor exposure: First case reported

Alan Hirsch, MD, founder and neurologic director of the Smell & Taste Treatment and Research Foundation, presented his research on Odor-Induced Pseudodystonia at the 3rd International Congress on Gait and Mental Function in Washington, D.C. on February 27.

2 Mar 2010

Movement Disorder News and Research

Latest Movement Disorder News and Research

TPP raises £9.6M to develop early-stage pre-clinical drug candidates

Being physical and mental activity delays onset of Huntington’s disease: Research

Imperial College London and McGill University expand scientific collaboration

Tel Aviv University researcher pioneers 3-D occupational therapy for children with disabilities

Aton Pharma acquires the U.S. marketing rights to LODOSYN tablets from BMS

Team of neurologists from the U.S. face Canadian neurologists in annual "Neurobowl"

New studies supporting Teva Pharmaceutical Industries' CNS portfolio to be presented at AAN 2010

Rexahn Pharmaceuticals submits Phase II protocol for study of Serdaxin in treatment of PD

Top neurologists to receive 2010 AAN Alliance Awards

New devices pave way for applications in cardiology and neurology

St. Jude Medical's Brio DBS system for treating Parkinson’s disease receives Australian TGA approval

Rexahn Pharmaceuticals forms Parkinson’s Disease SAB to develop strategy for Serdaxin

Manhattan Pharmaceuticals to merge with Ariston Pharmaceuticals

Ampicillin activates torsinA, improves cell function to reduce movement disorders

DSPA's lurasidone NDA accepted for FDA review

Omeros obtains exclusive license to compounds from Asubio Pharma for use in its PDE7 program

NAF to hold third annual Ataxia Investigators Meeting in Rosemont

Parkinson's patients find facial and vocal expression difficult to read; deep brain stimulation seems to make it worse

Allergan celebrates 20th anniversary of BOTOX in Canada

Focal dystonia precipitated by odor exposure: First case reported

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Movement Disorder News and Research

Latest Movement Disorder News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in